Fluvoxamine IR (Immediate-Release) is the Appropriate Formulation for Trichotillomania
For trichotillomania, use fluvoxamine immediate-release (IR) formulation, as this is the only FDA-approved formulation studied and indicated for obsessive-compulsive and related disorders. There is no extended-release (ER) formulation of fluvoxamine approved or studied for trichotillomania.
Formulation Availability and Evidence
The FDA-approved fluvoxamine formulation is immediate-release only 1. The drug label specifies dosing for fluvoxamine maleate tablets (IR formulation) for OCD, which is the closest FDA-approved indication to trichotillomania, as both are classified as obsessive-compulsive and related disorders 2.
Fluvoxamine IR dosing for adults: Start 50 mg at bedtime, titrate by 50 mg increments every 4-7 days as tolerated, up to 300 mg/day maximum. Doses above 100 mg should be split twice daily, with the larger dose at bedtime 1.
Evidence for Fluvoxamine in Trichotillomania
The evidence for fluvoxamine specifically in trichotillomania is limited and not particularly strong:
- One open-label trial (n=21) showed modest improvement in some measures of distress and control, but not robust hair-pulling reduction 3
- Meta-analyses consistently show SSRIs as a class (including fluvoxamine) have minimal to no efficacy for trichotillomania, with effect sizes near zero (ES = 0.02) 4, 5
- Behavioral therapy with habit reversal demonstrates far superior efficacy (ES = -1.14) compared to SSRIs 4, 5
Important Prescribing Considerations for Fluvoxamine
Fluvoxamine has greater potential for drug-drug interactions than other SSRIs because it inhibits multiple CYP450 enzymes (CYP1A2, CYP2C19, CYP2C9, CYP3A4, and CYP2D6) 6. Exercise caution with concomitant medications metabolized by these pathways.
Fluvoxamine is associated with discontinuation syndrome (more so than some other SSRIs but less than paroxetine), characterized by dizziness, sensory disturbances, nausea, and anxiety 6. Taper gradually rather than stopping abruptly 1.
Clinical Algorithm for Trichotillomania Treatment
Given the evidence hierarchy:
First-line: Behavioral therapy with habit reversal training (strongest evidence) 4, 5, 7
Pharmacological options if behavioral therapy insufficient or unavailable:
SSRIs including fluvoxamine: Consider only if comorbid anxiety or depression is prominent, as they show minimal direct benefit for hair-pulling behavior 8, 11, 9, 4
Critical Caveat
There is no evidence supporting fluvoxamine ER for trichotillomania because fluvoxamine ER is not the standard FDA-approved formulation for OCD-spectrum disorders. If you are considering fluvoxamine at all (which should be a lower-priority choice given the evidence), use only the immediate-release formulation with the dosing schedule specified in the FDA label 1.
The twice-daily dosing requirement for fluvoxamine IR at therapeutic doses (>100 mg/day) may actually be problematic for adherence compared to once-daily SSRIs like fluoxetine or sertraline 6. Consider alternative SSRIs with better tolerability profiles and once-daily dosing, or preferably, non-SSRI options like N-acetylcysteine combined with behavioral therapy 5, 7, 10.